MAPK3 and non-small cell lung carcinoma: Taken together, these results demonstrate that FXR upregulates HVEM via transcriptional activation; intracellular Akt, Erk1/2, and STAT3 signaling pathways; and cell cycle G1/S progression in NSCLC.